Max Lebeau (@maxmxndt) 's Twitter Profile
Max Lebeau

@maxmxndt

Invests in health and bio |
PhD @maxplanckpress |
Co-founder @gasb_synbio

ID: 708562675823988736

linkhttps://www.linkedin.com/in/maxmundt/ calendar_today12-03-2016 07:58:01

850 Tweet

1,1K Followers

824 Following

Sensible Biotechnologies (@sensible_bio) 's Twitter Profile Photo

As our CEO Miroslav Gasparek said, we are excited to partner with Ginkgo Bioworks on building a cell-based mRNA #biomanufacturing platform to unlock the full potential of #mRNA therapies. Many thanks to Jason Kelly, Austin Che & the team!

Miroslav Gasparek (@mirogasparek) 's Twitter Profile Photo

Excited that Sensible Biotechnologies raised $4.2mn pre-seed round led by BlueYard Capital to build cell-based platform for cost-efficient #production of high-quality #mRNA. Thrilled to be supported with top investors & partner with Ginkgo Bioworks to make better mRNA. Thread 1/n prnewswire.com/news-releases/…

Amino Collective (@aminocollective) 's Twitter Profile Photo

The key to scaling RNA therapies! We're excited to be supporting Miro and the team at Sensible Bio in their quest to remove the manufacturing bottleneck in mRNA production.

Elliot Hershberg (@elliothershberg) 's Twitter Profile Photo

For bio-entrepreneurs, Peter Marks from the FDA recently talked about bottlenecks that need to be solved to scale the number of gene therapy approvals. A big problem: scaling manufacturing. Source: fiercebiotech.com/biotech/thats-…

Max Lebeau (@maxmxndt) 's Twitter Profile Photo

The manufacturing bottleneck affects every sector that uses wetware (cells, proteins, nucleic acids etc), even cell and gene therapy. The FDA highlights that "making the manufacturing process for gene therapies more efficient is a critical next step". fiercebiotech.com/biotech/thats-…

The Genetic Underground (@geneticundrgrnd) 's Twitter Profile Photo

1/🧪Biopunks & mavericks, it's time to put on your lab coats & dancing kicks and RSVP! The Genetic Underground Biopunk Rave thegeneticunderground.com is FINALLY happening May 24th 7pm-12 in Oakland, CA @ The New Parish. Been incubating this in our petri dish w/ Cultured Supply 🧫

ValleyDAO (@valley_dao) 's Twitter Profile Photo

We’re kicking up a DeSci storm at the next edition of BUIDL LDN! 👾 Come and join Morgan Richards Alfred Brown Max Lebeau and Sarah Rouse from SpaceBioDAO as we explore the basics of DeSci and how you can get involved in the scientific revolution. 🔬⚗️🧬🥼

SynBioBeta (@synbiobeta) 's Twitter Profile Photo

The European bioeconomy is accelerating. European synbio products are entering the market, delivering for investors, and fueling sustainable policy agendas. Join the discussion at #SynBioBeta2023: synbiobeta.com Max Lebeau

The European bioeconomy is accelerating. European synbio products are entering the market, delivering for investors, and fueling sustainable policy agendas. Join the discussion at #SynBioBeta2023: synbiobeta.com <a href="/maxmxndt/">Max Lebeau</a>
lab.bio 💚🥼 (@lab_dao) 's Twitter Profile Photo

How are we aiming to decentralise drug discovery? We are building an exchange where scientists can trade laboratory and computational services - Check out 🌱PLEX docs.labdao.xyz

GASB SynBio (@gasb_synbio) 's Twitter Profile Photo

📢RT appreciated: Together we grow #SyntheticBiology! Join the SynBio World Cafe, our annual networking event for #SynBio though leaders. Sponsored by GASB, SPRIND, and TU Darmstadt. Apply by June 15. Connect with SynBio pioneers in Germany and Europe! synbioworldcafe.de

📢RT appreciated: 
Together we grow #SyntheticBiology! Join the SynBio World Cafe, our annual networking event for #SynBio though leaders. Sponsored by GASB, SPRIND, and TU Darmstadt. Apply by June 15. Connect with SynBio pioneers in Germany and Europe!

synbioworldcafe.de
Nicholas Sarai (@nicholassarai) 's Twitter Profile Photo

During my PhD with Frances Arnold Caltech we taught nature to break man-made bonds. Excited to share our report in @sciencemagazine using #directedevolution to engineer the first #enzyme that can cleave silicon–carbon bonds in non-biodegradable siloxanes! science.org/doi/10.1126/sc…

Max Lebeau (@maxmxndt) 's Twitter Profile Photo

The vast majority (16 of 17) of approved T-cell and gene therapies uses viral vectors. 5 of the 7 approved in vivo gene therapies use AAVs.

The vast majority (16 of 17) of approved T-cell and gene therapies uses viral vectors. 

5 of the 7 approved in vivo gene therapies use AAVs.